

Low-Value Clinical Practices In Adult Traumatic Brain Injury: An Umbrella Review

Lynne Moore (✉ lynne.moore@fmed.ulaval.ca)

Université Laval <https://orcid.org/0000-0002-6143-8888>

Pier-Alexandre Tardif

Université Laval

François Lauzier

Université Laval

Mélanie Bérubé

Université Laval

Patrick Archambault

Université Laval

François Lamontagne

Université de Sherbrooke

Michael Chassé

Université de Montréal

Henry T Stelfox

University of Calgary

Belinda Gabbe

Monash University

Fiona Lecky

University of Sheffield

John Kortbeek

University of Calgary

Paule Lessard-Bonaventure

Université Laval

Catherine Truchon

INESS

Alexis Turgeon

Université Laval

Research

Keywords: Low-value clinical practices, traumatic brain injury, umbrella review

Posted Date: January 23rd, 2020

DOI: <https://doi.org/10.21203/rs.2.21710/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

Version of Record: A version of this preprint was published at Journal of Neurotrauma on December 15th, 2020. See the published version at <https://doi.org/10.1089/neu.2020.7044>.

Abstract

Background Despite numerous interventions and treatment options, the outcomes of traumatic brain injury (TBI) have improved little over the last three decades, which raises concern about the value of care in this patient population. We aimed to synthesize the evidence on 14 potentially low-value clinical practices in TBI care.

Methods Using umbrella review methodology, we identified systematic reviews evaluating the effectiveness of 14 potentially low-value practices in adults with acute TBI. We present data on methodological quality (AMSTAR-2), reported effect sizes and credibility of evidence (I to IV).

Results The only clinical practice with evidence of benefit was therapeutic hypothermia (credibility of evidence II to IV). However, the most recent meta-analysis on hypothermia based on high-quality trials suggested harm (credibility of evidence IV). Meta-analyses on platelet transfusion for patients on antiplatelet therapy were all consistent with harm but were statistically non-significant. For the following practices, effect estimates were consistently close to the null: CT in adults with mild TBI who are low-risk on a validated clinical decision rule; repeat CT in adults with mild TBI on anticoagulant therapy with no clinical deterioration; antibiotic prophylaxis for external ventricular drain placement; and decompressive craniectomy for refractory intracranial hypertension.

Conclusions We identified five clinical practices with evidence of lack of benefit or harm. However, evidence could not be considered to be strong for any clinical practice as effect measures were imprecise and heterogeneous, systematic reviews were often of low quality and most included studies had a high risk of bias. Protocol registration PROSPERO: CRD42019132428

Introduction

Traumatic brain injury (TBI) is the main cause of mortality from injury in people under 45 years of age[1] and leads to US\$60 and €33 billion in medical costs in the USA[2] and Europe[3] each year. Moreover, outcomes following TBI have not improved significantly in the last four decades.[4,5] Treatment options for TBI are multiple, but many lack robust evidence of their effectiveness.[6,7]

Low-value clinical practices, defined as '*a test or procedure that is not supported by evidence and/or could expose patients to unnecessary harm*'[8-15] consume up to 30% of healthcare resources.[16,9] In the past decade, the medical community has turned towards the de-adoption of low-value practices as a promising means to reduce the strain on healthcare budgets, free-up resources and reduce harm to patients.[17] Physicians report using low-value practices because of a lack of alternative treatment options, fear of legal consequences, and a lack of guidelines on low-value care.[15,18] The *Brain Trauma Foundation*, among others, publishes guidelines on TBI care.[19] However, emphasis is on practices that should be adhered to rather than practices that should be avoided. *Choosing Wisely* publishes recommendations specifically targeting low-value practices, but few pertain to TBI care and many are based uniquely on expert consensus.[11] A previous scoping review and expert consultation survey identified 14 potentially low-value clinical practices in acute TBI care.[20] These practices represent potential targets for guidelines, overuse metrics and de-adoption interventions. However, before recommendations can be made, we need to synthesize the evidence base for these practices. The objective of the present study was to synthesize the evidence on potentially low-value intra-hospital clinical practices in acute TBI in adults.

Methods

Given the multitude of systematic reviews available for the clinical practices identified as potentially low-value,[20] we opted to conduct an umbrella review (a review of systematic reviews).[21] Our umbrella review was conducted according to published guidelines.[22-24] In the absence of reporting guidelines for umbrella reviews, we used applicable Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA).[25] The protocol was published[26] and registered with the International Prospective Register of Systematic Reviews (PROSPERO: CRD42019132428). An ethics waiver was obtained from the CHU de Québec – Université Laval research ethics board.

Eligibility criteria

We considered systematic reviews of original studies evaluating the effectiveness of any of the 14 clinical practices previously identified in a scoping review and expert consultation study [20] in acute TBI in adults (exclusively ≥ 16 years old or less than 20% <16 years old). We limited the search to systematic reviews published in English since 1990, in line with umbrella review guidelines.[23,24] The project steering committee comprising clinicians (two emergency physicians, seven critical care physicians, and one neurosurgeon), four methodologists, and three health system managers used the Population, Intervention, Comparator, Outcome and Study design (PICOS) framework to develop specific research questions for each of the 14 clinical practices (Additional file 1).[27,20]

We used the Cochrane definition to identify systematic reviews; we considered a review to be systematic if it clearly stated a set of objectives and reported explicit eligibility criteria, an extensive search strategy (a refined search strategy ran on MEDLINE or the Cochrane Library and at least one other database)[28,29] and reproducible methods to identify, select, and critically appraise the findings of the included systematic reviews.[22]

Outcomes

Primary and secondary outcomes were identified for each of the 14 clinical practices by the project steering committee and are described in PICOS format in Additional file 1. The most common were intracranial injury for diagnostic interventions and the Glasgow Outcome Scale (GOS) or the GOS-Extended (GOS-E) for therapeutic interventions.

Search strategy

We developed comprehensive literature search strategies separately for each clinical practice on consultation with an information specialist (see Additional file 2 for PubMed search strategies). We searched systematic reviews using the Cochrane Library, Excerpta Medica Database (EMBASE), Epistemonikos,[30] Medical Literature Analysis and Retrieval System Online (MEDLINE) and the International Prospective Register of Systematic Reviews (PROSPERO)[31] from 1990 to up to six months prior to submission for publication. Using a snowball approach, we then screened the references of included studies in addition to previous reviews on this subject.[7,32-35]

Selection process

We managed all citations with EndNote software (version X8.2, Clarivate Analytics, 2014). We identified and removed duplicates using electronic and manual screening.[36] To ensure reliability when selecting studies for a given practice, two sets of 100 citations were independently evaluated and then discussed by the reviewers. Pairs of reviewers (PAT, LM, IF) independently screened all identified records using titles, abstracts and full texts, consecutively. Any disagreement was resolved through discussion between reviewers and, if necessary, consultation with a senior author (AFT).

Data items and abstraction process

Using a standardized data abstraction form piloted on a representative sample of 5 systematic reviews, pairs of experienced reviewers (PAT, LM, IF) independently extracted the following data: first author, title, year of publication, databases used and date of the last search; population(s), intervention(s), comparator(s), outcome(s) and study designs included; measures of association and their respective measures of heterogeneity; risk of bias in original studies; and GRADE rating, when available. Any disagreement was resolved through discussion between reviewers and, if necessary, consultation with a senior author (AFT). When information was unclear or unavailable, we contacted systematic review authors with up to three email attempts.

Methodological quality assessment

Two reviewers (PAT, LM) independently critically appraised the quality of systematic reviews using the Assessing the Methodological Quality of Systematic Reviews (AMSTAR-2) tool. Methodological quality was categorised as critically low, low, moderate or high.[37]

Synthesis

Results are presented according to current recommendations for umbrella reviews.[38] For each low-value practice and each review, we present the number of studies according to their design, the sample size, the quality of the reviews (AMSTAR-2), measures of association for primary and secondary outcomes with their measures of heterogeneity, reported risk of bias for included studies, and reported strength of evidence (GRADE).[26] As GRADE was only used in 6/44 systematic reviews, we also evaluated evidence with credibility of evidence criteria used in previous umbrella reviews.[39,40] These criteria class evidence from meta-analyses into four categories: convincing (class I), highly suggestive (class II), suggestive (class III), weak (class IV) and non-significant (NS), based on statistical significance, sample size, heterogeneity and risk of bias.

Results

Of 8,455 citations identified in the initial search, we assessed 212 full texts for eligibility (Figure 1). Of these, 44 were deemed eligible and included in the synthesis (Additional file 3). Details of excluded systematic reviews are provided in Additional file 4.

Description of included reviews

At least one systematic review was identified for ten out of 14 targeted low-value practices (Table 1). Systematic reviews conducted within the last five years were available for nine clinical practices and meta-analyses were available for eight practices. The number of systematic reviews varied from one for plasma transfusion and neuromuscular blocking agents to 19 for hypothermia. Reviews on imaging mostly defined primary outcomes as intracranial injury, neurological deterioration or neurosurgical intervention, and their population as patients with mild or mild complicated TBI. Systematic reviews on therapeutic interventions mainly focussed on the GOS or GOS-Extended, mortality, or adverse events in patients with moderate to severe TBI. Most systematic reviews restricted their population of interest to adults but some included pediatric patients. Nine systematic reviews did not specify targeted study designs in their PICOS. In 20 other systematic reviews, only RCTs were included and in 14 both randomized controlled trials and observational studies were considered.

Methodological quality of systematic reviews

Of the 44 included systematic reviews, two[41,42] were rated high quality and eight[43-50] moderate quality (Additional file 5). All but two reviews[51,52][51, 52] used a comprehensive research strategy (95%), 17 (38%) established methods prior to the review and reported significant deviations from the study protocol, 34 (76%) used a satisfactory technique for reporting risk of bias, 20 (45%) accounted for risk of bias in individual studies when interpreting/discussing results, 33 out of the 34 reviews (97%) performing meta-analyses used appropriate analytic methods, and 20 (59%) investigated the presence of publication bias and discussed its potential impact on the results of meta-analyses.

Synthesis of results

Primary outcomes

Diagnostic interventions

We identified two reviews for CT in adults with mild TBI (both without meta-analyses),[44,53] but only one presented data allowing us to calculate point estimates for our primary outcome:[44] less than 5% of patients who were classed as low-risk (any decision rule) had intracranial injury (Table 2). Sample sizes were large for studies using the Canadian CT Head Rule (CCHR), the CT in Head Injury Patients (CHIP) rule and National Emergency X-Radiography Utilization Study (NEXUS) rule, but none of the included studies were at low risk of bias. In adults with acute mild complicated TBI (abnormal initial CT) with no neurological deterioration, routine repeat CT detected progression of intracranial hemorrhage in around 20% of patients. Routine repeat head CT led to the detection of delayed intracranial in only 0.6% of adults with mild TBI on anticoagulant or antiplatelet therapy.[54]

Therapeutic interventions

We identified two systematic reviews with meta-analyses on platelet transfusion in adults with TBI on antiplatelet therapy, which suggested increased risk of mortality in patients receiving the intervention, but estimates were imprecise and all CIs included the null value.[46,55] The systematic review on antibiotic prophylaxis for basal skull fracture suggested that the intervention is associated with reduced odds of meningitis, but again the estimates were imprecise and covered the null value.[47] A systematic review by the same group reported no benefit of antibiotic prophylaxis for external ventricular drain placement in severe TBI in terms of risk of infection.[41] We identified four systematic reviews with meta-analyses on seizure prophylaxis extended for more than one week after injury.[56,57,48,58] Odds ratio (OR) and risks ratio (RR) varied from 0.40 to 1.28 across systematic reviews. The most widely studied drug, levetiracetam, was associated with a potential reduction in late seizures, but with confidence intervals (CI) covering the null value. Fifteen out of the nineteen systematic reviews identified for therapeutic hypothermia performed meta-analyses with the GOS as the primary outcome.[59-64,43,65,42,66,49,67,52,68,69] OR/RRs varied between 0.61 and 1.16 with 11 suggesting significant benefit (credibility of evidence 3 class II,[43,42,69] three class III[65,67,68] and 5 class IV[61-64,42]) and one[69] (the most recent) suggesting significant harm (class IV). In five meta-analyses on high-quality studies, OR/RR either covered the null value (n=3),[64,65,49] suggested significant harm (n=1)[69] or suggested significant benefit (n=1).[42] Finally, we identified six systematic reviews on decompressive craniectomy,[70-75] of which four presented quantitative synthesis on GOS.[70,71,74,75] All were based exclusively on RCTs but were of low or critically low quality and had highly heterogeneous point estimates ($I^2 \geq 72\%$). Effect estimates were consistently close to one with CI covering the null value, suggesting no significant difference in outcome between intervention and control groups.

Secondary outcomes

Close to 0% of adults with mild TBI who were at low risk on a clinical decision rule for head CT required neurosurgical intervention (Additional file 6).[44] Routine repeat head CT in mild complicated TBI without neurological deterioration led to a neurosurgical intervention in between 0.6 and 2.4% of patients,[76-78] a change in clinical management in between 0.6[77] and 3.9%[78] and a change in intracranial pressure (ICP) monitoring in 1.2%.[78] Less than 0.2% of adults with mild TBI on anticoagulant or antiplatelet therapy with a routine repeat CT required neurosurgical treatment or died in hospital.[54]

Authors of the single systematic review on antibiotic prophylaxis in adults with basal skull fractures reported no reduction in all-cause or meningitis-related mortality.[47] In, eight of the 15 systematic reviews on hypothermia, a statistically significant reduction in the risk or odds of mortality was observed whereas one review observed an increase.[61,64,43,65,67,68,50,69] Five out of seven reviews that looked at pneumonia suggested higher risk/odds of this adverse event in adults receiving therapeutic hypothermia.[59,64,49,67,69] All of the four systematic reviews on decompressive craniectomy looked at mortality;[71,73-75] three observed a statistically lower risk in the intervention group at 6 months.[73-75] Finally, two systematic reviews on decompressive craniectomy observed

significantly lower mean intracranial pressure and shorter length of stay in the intervention group but significantly higher risk/odds of complications.[73,75]

Discussion

In this umbrella review on potentially low-value clinical practices in acute TBI care, the only clinical practices with any evidence of clinical benefit were routine repeat CT in mild complicated TBI (detection of progression of intracranial hemorrhage around 20%) and hypothermia (credibility of evidence II to IV). However, the most recent review for hypothermia based on high-quality trials suggested harm (credibility of evidence IV).[69] Meta-analyses on antibiotic prophylaxis in basal skull fractures all reported effect estimates consistent with clinically significant benefit but were statistically non-significant.[47] Meta-analyses on anti-platelet transfusion for adults with acute TBI on antiplatelet therapy all reported effect estimates consistent with clinically significant harm but were again statistically non-significant.[46,55] For the following practices, effect estimates were consistently close to the null value suggesting no clinical benefit: CT in adults with mild TBI who are at low-risk on a validated clinical decision rule;[44] repeat CT in adults with mild TBI on anticoagulant or antiplatelet therapy with no clinical deterioration;[54] antibiotic prophylaxis for external ventricular drain placement;[41] and decompressive craniectomy for patients with refractory intracranial hypertension.[71,68,74,75] However, confidence intervals were all wide.

Three clinical practices pertained to low-value imaging, which leads to increased costs, delays in care for other patients who require diagnostic imaging and is associated with an increased lifelong risk of cancer.[79-81] The review on CT in adults with mild TBI suggested less than 5% of patients who are at low-risk on a validated clinical decision rule had intracranial injury and less than 0.04% required neurosurgical intervention.[44] These results are in line with the inclusion of this practice as low-value in internationally recognized guidelines (*National Institute for Health and Care Excellence* [NICE], *Choosing Wisely*).[82,11] Less than 1% of adults with mild TBI on anticoagulant or antiplatelet therapy showed progression of hemorrhage on repeat CT or had poor outcomes.[54] However, the only systematic review on the subject was of very low quality. Evidence of low-value care for routinely repeating head CT in mild complicated TBI was less convincing with around one in five patients showing progression of hemorrhage.[76,77,83] This suggests the need to develop predictive models to more accurately identify patients at low risk of progression to avoid unnecessary repeat head CT scans in this population. It may also suggest that progression of intracranial hemorrhage is not the most clinically relevant outcome; repeat CT led to a change in clinical management (i.e. change in ICP monitoring, drug therapy or neurosurgical intervention based on CT results) in less than 4% of patients (secondary outcome).[76-78] This observation also brings up the question of how our threshold of tolerance for false negatives should vary according to the severity of the consequences of missing a case.

In terms of therapeutic interventions, evidence for platelet transfusion in adults on antiplatelet therapy suggested low-value care, with a non-significant increase in mortality in all systematic reviews.[46,55] Antiplatelet therapy was used in between 3% to 42% of these patients and given the adverse events associated with this practice, its de-adoption has the potential to improve patient outcomes in addition to freeing-up resources. However, reviews were based on retrospective cohorts and evidence was graded as very low in all cases. A systematic review of moderate

quality based on RCTs suggested a possible beneficial effect of antibiotic prophylaxis in adults with basal skull fractures with or without CSF leakage with evidence of moderate strength according to GRADE.[47] However, OR were imprecise with 95% CI covering the null value. The only review on antibiotic prophylaxis for external ventricular drain placement included one RCT which suggested no benefit in terms of infection incidence but this was based on a very imprecise pooled estimate and unclear risk of bias.[41] Evidence on extended antiseizure prophylaxis was inconsistent; most point estimates suggested a protective effect, but all CI covered the null value. The review including the most RCTs (n=6; also with the highest methodological quality) observed a null effect and graded the evidence as very low regarding carbamazepine and phenytoin whereas the most recent review (critically low quality) observed a non-significant protective effect and graded evidence as high for levetiracetam and phenytoin. [48]

For therapeutic hypothermia, multiple large RCTs have been conducted (the most comprehensive systematic review included 22 RCTs)[69] and targeted populations and interventions have changed over the years. The latest high-profile trials evaluated therapeutic hypothermia in all adults admitted to the ICU after a closed TBI with ICP>20 mm Hg for at least 5 minutes after stage I treatments (Eurotherm3235 Trial)[84] and prophylactic hypothermia in adults with severe TBI regardless of ICP prior to randomisation (POLAR-RCT).[85] POLAR-RCT was not included in any systematic review we identified. Recruitment in the Eurotherm3235 Trial was stopped early since preliminary results suggested harm in the intervention arm (6-month mortality, hazard ratio: 1.45 [95 % CI: 1.01-2.10]). Moreover, results from the POLAR-RCT were compatible neither with harm nor benefit on six-month GOS-E (RR: 0.99 [95 % CI: 0.82-1.19]) and six-month mortality (RR: 1.15 [95 % CI: 0.80-1.64]. In line with these two RCTs, the most recent meta-analyses on RCTs with a low risk of bias suggest that therapeutic hypothermia is associated with no benefit or harm.[69] Among changes in these recent trials which may explain observed differences are the application of a normotherapy protocol in the control group.

For decompressive craniectomy, point estimates for unfavorable outcome were close to the null value and statistically non-significant indicating no significant benefit of the intervention in terms of reduction in unfavorable outcome (GOS 1-4) at 6 months. Results are mostly driven by two large high-profile RCTs (DECRA[86] and RESCUE-ICP[87]) that were both included in three of the four systematic reviews we identified. In the DECRA trial, decompressive craniectomy was conducted as a second-tier therapy; a statistically non-significant increase in unfavorable outcome at six months for the intervention group and no difference in mortality were observed. In the RESCUE-ICP trial, decompressive craniectomy was conducted as a third-tier therapy; the intervention group had significantly lower mortality at 6 months but no difference in unfavorable outcome was observed (gains in survival translated into more patients with severe disability). The systematic reviews we identified for this clinical practice had critical methodological flaws. Of note, Lu and colleagues[75] considered the GOS-E at 6 months for DECRA but at 12 months for RESCUE-ICP whereas Tsaousi[74] and Zhang[73] considered a GOS-E of three and less as an unfavorable outcome, therefore considering upper severe disability as favorable. This led to an overestimation of the benefit of the intervention in both cases. Since the publication of DECRA and RESCUE-ICP, a consensus statement has been published recognizing the lack of evidence of effectiveness for improving patient outcome but recommending (based solely on consensus) decompressive craniotomy in specific situations, often dictated by physician gestalt and physician-family shared decision-making.[88]

Limitations

This review does have limitations which should be considered in the interpretation of results. First, to ensure the feasibility of the review, we restricted our search to the 14 low-value practices identified previously in a scoping review and expert consultation study,[20] which may have led us to miss some low-value practices. However, given the exhaustive search strategy used in the scoping review and the fact that experts were asked to add any other practices they considered low-value, it is unlikely that important low-value practices have been missed. Second, by targeting systematic reviews rather than original studies, we may have missed some evidence. For three clinical practices, we did not identify any systematic reviews, namely ICU admission in adults with acute mild complicated TBI who are not on direct oral anticoagulants, neurosurgical consultation in adults with acute mild TBI with normal head CT and albumin administration in severe TBI. In addition, for plasma transfusion and neuromuscular blocking agents, all identified studies were qualitative. Furthermore, systematic reviews may not convey the most up-to-date evidence or meet high quality standards. For example, at least one high-profile RCT has been published on hypothermia since the update of the most recent systematic review (POLAR trial)[85] and systematic reviews on decompressive craniectomy all had critical methodological flaws.[85] Fourth, meta-analysis results may not convey heterogeneity in effects, as indicated by the high heterogeneity of pooled estimates in many systematic reviews. For example, we may have missed differential effects of decompressive craniectomy as a second-tier or third-tier therapy or of therapeutic hypothermia according to timing and target temperature. Unfortunately, low numbers of studies precluded subgroup analyses for these factors. Fifth, all included reviews/studies aimed to demonstrate effectiveness (superiority trials) and were therefore not designed to formulate conclusions on low-value care (i.e. lack of effectiveness or harm). For this, inferiority trials would be necessary. Finally, for feasibility reasons, we limited this umbrella review to systematic reviews published in English since 1990 as per recommendations for umbrella reviews.[23,24] These limitations should have a negligible impact on results since no systematic reviews were published prior to 1990 (the first review identified was published in 2001) and most published reviews are written in English.[24,23] Among the 23 studies excluded based on language, only two were eligible based on the English abstract (published in Mandarin and Romanian) and their reported results (again from the abstract) were concordant with those of reviews included in our study.

Conclusion

We found low-grade evidence that the following clinical practices are either not beneficial or harmful: CT in adults with mild TBI who are at low-risk on a clinical decision rule; repeat CT for adults with mild TBI on anticoagulant or antiplatelet therapy prior to injury; platelet transfusions in adults on antiplatelet therapy; antibiotic prophylaxis for external ventricular drain placement; and decompressive craniectomy in patients with refractory intracranial hypertension. In addition, the most recent systematic review on high quality trials suggest that hypothermia is associated with harm when compared to normothermia. We should now strive to measure the prevalence of these practices and assess inter-provider variation. Conditional on the results of future research, they may represent targets for de-adoption interventions to improve value in care for adults with acute TBI. The reduction of low-value clinical practices in this patient population has the potential to reduce pressure on strained healthcare budgets, free up resources, reduce adverse events and improve patient outcomes.

References

1. The American Association for the Surgery of Trauma (AAST) (December 1999) Traumatic Brain Injury in the United States: A Report to Congress, CDC,. <http://www.aast.org/trauma-facts>.
2. Coronado VG, Haileyesus T, Cheng TA, Bell JM, Haarbauer-Krupa J, Lionbarger MR, Flores-Herrera J, McGuire LC, Gilchrist J (2015) Trends in Sports- and Recreation-Related Traumatic Brain Injuries Treated in US Emergency Departments: The National Electronic Injury Surveillance System-All Injury Program (NEISS-AIP) 2001-2012. *J Head Trauma Rehabil* 30 (3):185-197. doi:10.1097/HTR.0000000000000156
3. Olesen J, Gustavsson A, Svensson M, Wittchen HU, Jonsson B, group Cs, European Brain C (2012) The economic cost of brain disorders in Europe. *Eur J Neurol* 19 (1):155-162. doi:10.1111/j.1468-1331.2011.03590.x
4. Rosenfeld JV, Maas AI, Bragge P, Morganti-Kossmann MC, Manley GT, Gruen RL (2012) Early management of severe traumatic brain injury. *Lancet* 380 (9847):1088-1098. doi:10.1016/S0140-6736(12)60864-2
5. Maas AIR, Menon DK, Adelson PD, Andelic N, Bell MJ, Belli A, Bragge P, Brazinova A, Buki A, Chesnut RM, Citerio G, Coburn M, Cooper DJ, Crowder AT, Czeiter E, Czosnyka M, Diaz-Arrastia R, Dreier JP, Duhaime AC, Ercole A, van Essen TA, Feigin VL, Gao G, Giacino J, Gonzalez-Lara LE, Gruen RL, Gupta D, Hartings JA, Hill S, Jiang JY, Ketharanathan N, Kompanje EJO, Lanyon L, Laureys S, Lecky F, Levin H, Lingsma HF, Maegele M, Majdan M, Manley G, Marsteller J, Mascia L, McFadyen C, Mondello S, Newcombe V, Palotie A, Parizel PM, Peul W, Piercy J, Polinder S, Puybasset L, Rasmussen TE, Rossaint R, Smielewski P, Soderberg J, Stanworth SJ, Stein MB, von Steinbuchel N, Stewart W, Steyerberg EW, Stocchetti N, Synnot A, Te Ao B, Tenovuo O, Theadom A, Tibboel D, Videtta W, Wang KKW, Williams WH, Wilson L, Yaffe K, In TP, Investigators (2017) Traumatic brain injury: integrated approaches to improve prevention, clinical care, and research. *Lancet Neurol* 16 (12):987-1048. doi:10.1016/S1474-4422(17)30371-X
6. Maas AI, Roozenbeek B, Manley GT (2010) Clinical trials in traumatic brain injury: past experience and current developments. *Neurotherapeutics* 7 (1):115-126. doi:10.1016/j.nurt.2009.10.022
7. Bragge P, Synnot A, Maas AI, Menon DK, Cooper DJ, Rosenfeld JV, Gruen RL (2016) A State-of-the-Science Overview of Randomized Controlled Trials Evaluating Acute Management of Moderate-to-Severe Traumatic Brain Injury. *J Neurotrauma* 33 (16):1461-1478. doi:10.1089/neu.2015.4233
8. Boat TF, Chao SM, O'Neill PH (2008) From waste to value in health care. *JAMA* 299 (5):568-571. doi:10.1001/jama.299.5.568
9. Reilly BM, Evans AT (2009) Much ado about (doing) nothing. *Annals of internal medicine* 150 (4):270-271
10. Berwick DM, Hackbarth AD (2012) Eliminating waste in US health care. *JAMA* 307 (14):1513-1516. doi:10.1001/jama.2012.362
11. Choosing Wisely Canada (2015). <https://choosingwiselycanada.org/>.
12. Morgan DJ, Dhruva SS, Wright SM, Korenstein D (2016) 2016 Update on Medical Overuse: A Systematic Review. *JAMA Intern Med* 176 (11):1687-1692. doi:10.1001/jamainternmed.2016.5381
13. Berwick DM (2017) Avoiding overuse-the next quality frontier. *Lancet* 390 (10090):102-104. doi:10.1016/S0140-6736(16)32570-3
14. Brownlee S, Chalkidou K, Doust J, Elshaug AG, Glasziou P, Heath I, Nagpal S, Saini V, Srivastava D, Chalmers K, Korenstein D (2017) Evidence for overuse of medical services around the world. *Lancet* 390 (10090):156-168. doi:10.1016/S0140-6736(16)32585-5

15. Saini V, Brownlee S, Elshaug AG, Glasziou P, Heath I (2017) Addressing overuse and underuse around the world. *Lancet* 390 (10090):105-107. doi:10.1016/S0140-6736(16)32573-9
16. Fisher ES, Wennberg DE, Stukel TA, Gottlieb DJ, Lucas FL, Pinder EL (2003) The implications of regional variations in Medicare spending. Part 2: health outcomes and satisfaction with care. *Annals of internal medicine* 138 (4):288-298
17. Niven DJ, Mrklas KJ, Holodinsky JK, Straus SE, Hemmelgarn BR, Jeffs LP, Stelfox HT (2015) Towards understanding the de-adoption of low-value clinical practices: a scoping review. *BMC Med* 13:255. doi:10.1186/s12916-015-0488-z
18. Emanuel EJ, Fuchs VR (2008) The perfect storm of overutilization. *JAMA* 299 (23):2789-2791. doi:10.1001/jama.299.23.2789
19. Carney N, Totten AM, O'Reilly C, Ullman JS, Hawryluk GW, Bell MJ, Bratton SL, Chesnut R, Harris OA, Kissoon N, Rubiano AM, Shutter L, Tasker RC, Vavilala MS, Wilberger J, Wright DW, Ghajar J (2017) Guidelines for the Management of Severe Traumatic Brain Injury, Fourth Edition. *Neurosurgery* 80 (1):6-15. doi:10.1227/NEU.0000000000001432
20. Moore L, Lauzier F, Tardif PA, Boukar KM, Farhat I, Archambault P, Mercier E, Lamontagne F, Chasse M, Stelfox HT, Berthelot S, Gabbe B, Lecky F, Yanchar N, Champion H, Kortbeek J, Cameron P, Bonaventure PL, Paquet J, Truchon C, Turgeon AF, Canadian Traumatic brain injury Research C (2019) Low-Value Clinical Practices in Injury Care: A Scoping Review and Expert Consultation Survey. *J Trauma Acute Care Surg*. doi:10.1097/TA.0000000000002246
21. Fusar-Poli P, Radua J (2018) Ten simple rules for conducting umbrella reviews. *Evid Based Ment Health* 21 (3):95-100. doi:10.1136/ebmental-2018-300014
22. Higgins J, Green S, (editors). (2011) *Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0* [updated March 2011]. The Cochrane Collaboration,
23. Smith V, Devane D, Begley CM, Clarke M (2011) Methodology in conducting a systematic review of systematic reviews of healthcare interventions. *BMC Med Res Methodol* 11 (1):15. doi:10.1186/1471-2288-11-15
24. The Joanna Briggs Institute (2014) *Joanna Briggs Institute Reviewers' Manual: 2014 edition / Supplement*. The Joanna Briggs Institute
25. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med* 6 (7):e1000097. doi:10.1371/journal.pmed.1000097
26. Tardif PA, Moore L, Lauzier F, Farhat I, Archambault P, Lamontagne F, Chasse M, Stelfox HT, Gabbe BJ, Lecky F, Kortbeek J, Lessard-Bonaventure P, Truchon C, Turgeon AF (2019) Low-value clinical practices in adult traumatic brain injury: an umbrella review protocol. *BMJ Open* 9 (10):e031747. doi:10.1136/bmjopen-2019-031747
27. Stone PW (2002) Popping the (PICO) question in research and evidence-based practice. *Appl Nurs Res* 15 (3):197-198
28. Marshall I, Marshall R, Wallace B, Brassey J, Thomas J (2018) Rapid reviews may produce different results to systematic reviews: a meta-epidemiological study. *J Clin Epidemiol*. doi:10.1016/j.jclinepi.2018.12.015
29. Bramer WM, Rethlefsen ML, Kleijnen J, Franco OH (2017) Optimal database combinations for literature searches in systematic reviews: a prospective exploratory study. *Systematic reviews* 6 (1):245-245. doi:10.1186/s13643-017-0644-y
30. Epistemonikos Epistemonikos n.d. <http://www.epistemonikos.org/en/>. Accessed November 19 2018

31. Centre for Reviews and Dissemination PROSPERO. <https://www.crd.york.ac.uk/PROSPERO/>. Accessed November 19 2018
32. Horton L, Rhodes J, Wilson L (2018) Randomized Controlled Trials in Adult Traumatic Brain Injury: A Systematic Review on the Use and Reporting of Clinical Outcome Assessments. *J Neurotrauma* 35 (17):2005-2014. doi:10.1089/neu.2018.5648
33. Lei J, Gao GY, Jiang JY (2012) Is management of acute traumatic brain injury effective? A literature review of published Cochrane Systematic Reviews. *Chin J Traumatol* 15 (1):17-22
34. Lu J, Gary KW, Copolillo A, Ward J, Niemeier JP, Lapane KL (2015) Randomized controlled trials in adult traumatic brain injury: a review of compliance to CONSORT statement. *Arch Phys Med Rehabil* 96 (4):702-714. doi:10.1016/j.apmr.2014.10.026
35. Synnot A, Bragge P, Lunny C, Menon D, Clavisi O, Pattuwage L, Volovici V, Mondello S, Cnossen MC, Donoghue E, Gruen RL, Maas A (2018) The currency, completeness and quality of systematic reviews of acute management of moderate to severe traumatic brain injury: A comprehensive evidence map. *PLoS One* 13 (6):e0198676. doi:10.1371/journal.pone.0198676
36. Bramer WM, Giustini D, de Jonge GB, Holland L, Bekhuis T (2016) De-duplication of database search results for systematic reviews in EndNote. *J Med Libr Assoc* 104 (3):240-243. doi:10.3163/1536-5050.104.3.014
37. Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, Moher D, Tugwell P, Welch V, Kristjansson E, Henry DA (2017) AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. *BMJ* 358:j4008. doi:10.1136/bmj.j4008
38. Lunny C, Brennan SE, McDonald S, McKenzie JE (2018) Toward a comprehensive evidence map of overview of systematic review methods: paper 2-risk of bias assessment; synthesis, presentation and summary of the findings; and assessment of the certainty of the evidence. *Syst Rev* 7 (1):159. doi:10.1186/s13643-018-0784-8
39. Theodoratou E, Tzoulaki I, Zgaga L, Ioannidis JP (2014) Vitamin D and multiple health outcomes: umbrella review of systematic reviews and meta-analyses of observational studies and randomised trials. *BMJ* 348:g2035. doi:10.1136/bmj.g2035
40. Li X, Meng X, Timofeeva M, Tzoulaki I, Tsilidis KK, Ioannidis JP, Campbell H, Theodoratou E (2017) Serum uric acid levels and multiple health outcomes: umbrella review of evidence from observational studies, randomised controlled trials, and Mendelian randomisation studies. *BMJ* 357:j2376. doi:10.1136/bmj.j2376
41. Ratalil B, Costa J, Sampaio C (2006) Antibiotic prophylaxis for surgical introduction of intracranial ventricular shunts. *Cochrane Database Syst Rev* (3):CD005365. doi:10.1002/14651858.CD005365.pub2
42. Crossley S, Reid J, McLatchie R, Hayton J, Clark C, MacDougall M, Andrews PJ (2014) A systematic review of therapeutic hypothermia for adult patients following traumatic brain injury. *Crit Care* 18 (2):R75. doi:10.1186/cc13835
43. Fox JL, Vu EN, Doyle-Waters M, Brubacher JR, Abu-Laban R, Hu Z (2010) Prophylactic hypothermia for traumatic brain injury: a quantitative systematic review. *CJEM* 12 (4):355-364. doi:10.1017/s1481803500012471
44. Pandor A, Goodacre S, Harnan S, Holmes M, Pickering A, Fitzgerald P, Rees A, Stevenson M (2011) Diagnostic management strategies for adults and children with minor head injury: a systematic review and an economic evaluation. *Health Technol Assess* 15 (27):1-202. doi:10.3310/hta15270
45. Yang L, Stanworth S, Fau - Hopewell S, Hopewell S, Fau - Doree C, Doree C, Fau - Murphy M, Murphy M (2012) Is fresh-frozen plasma clinically effective? An update of a systematic review of randomized controlled trials.

(1537-2995 (Electronic))

46. Kumar A, Mhaskar R, Grossman BJ, Kaufman RM, Tobian AA, Kleinman S, Gernsheimer T, Tinmouth AT, Djulbegovic B, Panel APTG (2015) Platelet transfusion: a systematic review of the clinical evidence. *Transfusion* 55 (5):1116-1127; quiz 1115. doi:10.1111/trf.12943
47. Ratilal BO, Costa J, Pappamikail L, Sampaio C (2015) Antibiotic prophylaxis for preventing meningitis in patients with basilar skull fractures. *Cochrane Database Syst Rev* (4):CD004884. doi:10.1002/14651858.CD004884.pub4
48. Thompson K, Pohlmann-Eden B, Campbell LA, Abel H (2015) Pharmacological treatments for preventing epilepsy following traumatic head injury. *Cochrane Database Syst Rev* (8):CD009900. doi:10.1002/14651858.CD009900.pub2
49. Zhu Y, Yin H, Zhang R, Ye X, Wei J (2016) Therapeutic hypothermia versus normothermia in adult patients with traumatic brain injury: a meta-analysis. *Springerplus* 5 (1):801. doi:10.1186/s40064-016-2391-2
50. Olah E, Poto L, Hegyi P, Szabo I, Hartmann P, Solymar M, Petervari E, Balasko M, Habon T, Rumbus Z, Tenk J, Rostas I, Weinberg J, Romanovsky AA, Garami A (2018) Therapeutic Whole-Body Hypothermia Reduces Death in Severe Traumatic Brain Injury if the Cooling Index Is Sufficiently High: Meta-Analyses of the Effect of Single Cooling Parameters and Their Integrated Measure. *J Neurotrauma* 35 (20):2407-2417. doi:10.1089/neu.2018.5649
51. Teasell R, Bayona N, Lippert C, Villamere J, Hellings C (2007) Post-traumatic seizure disorder following acquired brain injury. *Brain Inj* 21 (2):201-214. doi:10.1080/02699050701201854
52. Leng L (2017) Hypothermia Therapy after Traumatic Brain Injury: A Systematic Review and Meta-Analysis. *Turk Neurosurg*. doi:10.5137/1019-5149.JTN.19696-16.2
53. Easter JS, Haukoos JS, Meehan WP, Novack V, Edlow JA (2015) Will Neuroimaging Reveal a Severe Intracranial Injury in This Adult With Minor Head Trauma?: The Rational Clinical Examination Systematic Review. *JAMA* 314 (24):2672-2681. doi:10.1001/jama.2015.16316
54. Chauny JM, Marquis M, Bernard F, Williamson D, Albert M, Laroche M, Daoust R (2016) Risk of Delayed Intracranial Hemorrhage in Anticoagulated Patients with Mild Traumatic Brain Injury: Systematic Review and Meta-Analysis. *J Emerg Med* 51 (5):519-528. doi:10.1016/j.jemermed.2016.05.045
55. Leong LB, David TK (2015) Is Platelet Transfusion Effective in Patients Taking Antiplatelet Agents Who Suffer an Intracranial Hemorrhage? *J Emerg Med* 49 (4):561-572. doi:10.1016/j.jemermed.2015.02.023
56. Temkin NR (2001) Antiepileptogenesis and seizure prevention trials with antiepileptic drugs: meta-analysis of controlled trials. *Epilepsia* 42 (4):515-524. doi:10.1046/j.1528-1157.2001.28900.x
57. Chang BS, Lowenstein DH, Quality Standards Subcommittee of the American Academy of N (2003) Practice parameter: antiepileptic drug prophylaxis in severe traumatic brain injury: report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology* 60 (1):10-16. doi:10.1212/01.wnl.0000031432.05543.14
58. Wilson CD, Burks JD, Rodgers RB, Evans RM, Bakare AA, Safavi-Abbasi S (2018) Early and Late Posttraumatic Epilepsy in the Setting of Traumatic Brain Injury: A Meta-analysis and Review of Antiepileptic Management. *World Neurosurg* 110:e901-e906. doi:10.1016/j.wneu.2017.11.116
59. Harris OA, Colford JM, Jr., Good MC, Matz PG (2002) The role of hypothermia in the management of severe brain injury: a meta-analysis. *Arch Neurol* 59 (7):1077-1083. doi:10.1001/archneur.59.7.1077

60. Henderson WR, Dhingra VK, Chittock DR, Fenwick JC, Ronco JJ (2003) Hypothermia in the management of traumatic brain injury. A systematic review and meta-analysis. *Intensive Care Med* 29 (10):1637-1644. doi:10.1007/s00134-003-1848-2
61. McIntyre LA, Fergusson DA, Hebert PC, Moher D, Hutchison JS (2003) Prolonged therapeutic hypothermia after traumatic brain injury in adults: a systematic review. *JAMA* 289 (22):2992-2999. doi:10.1001/jama.289.22.2992
62. Brain Trauma F, American Association of Neurological S, Congress of Neurological S, Joint Section on N, Critical Care AC, Bratton SL, Chestnut RM, Ghajar J, McConnell Hammond FF, Harris OA, Hartl R, Manley GT, Nemecek A, Newell DW, Rosenthal G, Schouten J, Shutter L, Timmons SD, Ullman JS, Videtta W, Wilberger JE, Wright DW (2007) Guidelines for the management of severe traumatic brain injury. III. Prophylactic hypothermia. *J Neurotrauma* 24 Suppl 1:S21-25. doi:10.1089/neu.2007.9993
63. Peterson K, Carson S, Carney N (2008) Hypothermia treatment for traumatic brain injury: a systematic review and meta-analysis. *J Neurotrauma* 25 (1):62-71. doi:10.1089/neu.2007.0424
64. Sydenham E, Roberts I, Alderson P (2009) Hypothermia for traumatic head injury. *Cochrane Database Syst Rev* (2):CD001048. doi:10.1002/14651858.CD001048.pub4
65. Georgiou AP, Manara AR (2013) Role of therapeutic hypothermia in improving outcome after traumatic brain injury: a systematic review. *Br J Anaesth* 110 (3):357-367. doi:10.1093/bja/aes500
66. Li P, Yang C (2014) Moderate hypothermia treatment in adult patients with severe traumatic brain injury: a meta-analysis. *Brain Inj* 28 (8):1036-1041. doi:10.3109/02699052.2014.910609
67. Crompton EM, Lubomirova I, Cotlarciuc I, Han TS, Sharma SD, Sharma P (2017) Meta-Analysis of Therapeutic Hypothermia for Traumatic Brain Injury in Adult and Pediatric Patients. *Crit Care Med* 45 (4):575-583. doi:10.1097/CCM.0000000000002205
68. Zang Z, Xu X, Xu S (2017) The efficacy of therapeutic hypothermia in adult patients with traumatic brain injury: A systematic review and meta-analysis. *International Journal of Clinical and Experimental Medicine* 10 (6):8691-8699
69. Watson HI, Shepherd AA, Rhodes JKJ, Andrews PJD (2018) Revisited: A Systematic Review of Therapeutic Hypothermia for Adult Patients Following Traumatic Brain Injury. *Crit Care Med* 46 (6):972-979. doi:10.1097/CCM.0000000000003125
70. Barthelemy EJ, Melis M, Gordon E, Ullman JS, Germano IM (2016) Decompressive Craniectomy for Severe Traumatic Brain Injury: A Systematic Review. *World Neurosurg* 88:411-420. doi:10.1016/j.wneu.2015.12.044
71. Wang JW, Li JP, Song YL, Tan K, Wang Y, Li T, Guo P, Li X, Wang Y, Zhao QH (2016) Decompressive craniectomy in neurocritical care. *J Clin Neurosci* 27:1-7. doi:10.1016/j.jocn.2015.06.037
72. Abraham P, Rennert RC, Gabel BC, Sack JA, Karanjia N, Warnke P, Chen CC (2017) ICP management in patients suffering from traumatic brain injury: a systematic review of randomized controlled trials. *Acta Neurochir (Wien)* 159 (12):2279-2287. doi:10.1007/s00701-017-3363-1
73. Zhang D, Xue Q, Chen J, Dong Y, Hou L, Jiang Y, Wang J (2017) Decompressive craniectomy in the management of intracranial hypertension after traumatic brain injury: a systematic review and meta-analysis. *Sci Rep* 7 (1):8800. doi:10.1038/s41598-017-08959-y
74. Tsaousi GG, Marocchi L, Sergi PG, Pourzitaki C, Santoro A, Bilotta F (2018) Early and late clinical outcomes after decompressive craniectomy for traumatic refractory intracranial hypertension: a systematic review and meta-analysis of current evidence. *J Neurosurg Sci*. doi:10.23736/S0390-5616.18.04527-7

75. Lu G, Zhu L, Wang X, Zhang H, Li Y (2019) Decompressive Craniectomy for Patients with Traumatic Brain Injury: A Pooled Analysis of Randomized Controlled Trials. *World Neurosurg*. doi:10.1016/j.wneu.2019.08.184
76. Stippler M, Smith C, McLean AR, Carlson A, Morley S, Murray-Krezan C, Kraynik J, Kennedy G (2012) Utility of routine follow-up head CT scanning after mild traumatic brain injury: a systematic review of the literature. *Emerg Med J* 29 (7):528-532. doi:10.1136/emered-2011-200162
77. Almenawer SA, Bogza I, Yarascavitch B, Sne N, Farrokhyar F, Murty N, Reddy K (2013) The value of scheduled repeat cranial computed tomography after mild head injury: single-center series and meta-analysis. *Neurosurgery* 72 (1):56-62; discussion 63-54. doi:10.1227/NEU.0b013e318276f899
78. Reljic T, Mahony H, Djulbegovic B, Etchason J, Paxton H, Flores M, Kumar A (2014) Value of repeat head computed tomography after traumatic brain injury: systematic review and meta-analysis. *J Neurotrauma* 31 (1):78-98. doi:10.1089/neu.2013.2873
79. Mathews JD, Forsythe AV, Brady Z, Butler MW, Goergen SK, Byrnes GB, Giles GG, Wallace AB, Anderson PR, Guiver TA, McGale P, Cain TM, Dowty JG, Bickerstaffe AC, Darby SC (2013) Cancer risk in 680,000 people exposed to computed tomography scans in childhood or adolescence: data linkage study of 11 million Australians. *BMJ* 346:f2360. doi:10.1136/bmj.f2360
80. Pearce MS, Salotti JA, Little MP, McHugh K, Lee C, Kim KP, Howe NL, Ronckers CM, Rajaraman P, Sir Craft AW, Parker L, Berrington de Gonzalez A (2012) Radiation exposure from CT scans in childhood and subsequent risk of leukaemia and brain tumours: a retrospective cohort study. *Lancet* 380 (9840):499-505. doi:10.1016/S0140-6736(12)60815-0
81. Stein SC, Hurst RW, Sonnad SS (2008) Meta-analysis of cranial CT scans in children. A mathematical model to predict radiation-induced tumors. *Pediatr Neurosurg* 44 (6):448-457. doi:10.1159/000172967
82. National Institute for Health and Care Excellence (2019) Head injury: assessment and early management. <https://www.nice.org.uk/guidance/CG176>. Accessed September 4th 2019
83. Marincowitz C, Lecky FE, Townend W, Borakati A, Fabbri A, Sheldon TA (2018) The Risk of Deterioration in GCS13-15 Patients with Traumatic Brain Injury Identified by Computed Tomography Imaging: A Systematic Review and Meta-Analysis. *J Neurotrauma* 35 (5):703-718. doi:10.1089/neu.2017.5259
84. Andrews PJ, Sinclair HL, Rodriguez A, Harris BA, Battison CG, Rhodes JK, Murray GD, Eurotherm Trial C (2015) Hypothermia for Intracranial Hypertension after Traumatic Brain Injury. *N Engl J Med* 373 (25):2403-2412. doi:10.1056/NEJMoa1507581
85. Cooper DJ, Nichol AD, Bailey M, Bernard S, Cameron PA, Pili-Floury S, Forbes A, Gantner D, Higgins AM, Huet O, Kasza J, Murray L, Newby L, Presneill JJ, Rashford S, Rosenfeld JV, Stephenson M, Vallance S, Varma D, Webb SAR, Trapani T, McArthur C, Investigators PT, the ACTG (2018) Effect of Early Sustained Prophylactic Hypothermia on Neurologic Outcomes Among Patients With Severe Traumatic Brain Injury: The POLAR Randomized Clinical Trial. *JAMA* 320 (21):2211-2220. doi:10.1001/jama.2018.17075
86. Cooper DJ, Rosenfeld JV, Murray L, Arabi YM, Davies AR, D'Urso P, Kossmann T, Ponsford J, Seppelt I, Reilly P, Wolfe R, Investigators DT, Australian, New Zealand Intensive Care Society Clinical Trials G (2011) Decompressive craniectomy in diffuse traumatic brain injury. *N Engl J Med* 364 (16):1493-1502. doi:10.1056/NEJMoa1102077
87. Hutchinson PJ, Kolias AG, Timofeev IS, Corteen EA, Czosnyka M, Timothy J, Anderson I, Bulters DO, Belli A, Eynon CA, Wadley J, Mendelow AD, Mitchell PM, Wilson MH, Critchley G, Sahuquillo J, Unterberg A, Servadei F, Teasdale GM, Pickard JD, Menon DK, Murray GD, Kirkpatrick PJ, Collaborators RET (2016) Trial of

Decompressive Craniectomy for Traumatic Intracranial Hypertension. *N Engl J Med* 375 (12):1119-1130. doi:10.1056/NEJMoa1605215

88. Hutchinson PJ, Koltias AG, Tajsic T, Adeleye A, Aklilu AT, Apriawan T, Bajamal AH, Barthelemy EJ, Devi BI, Bhat D, Bulters D, Chesnut R, Citerio G, Cooper DJ, Czosnyka M, Edem I, El-Ghandour NMF, Figaji A, Fountas KN, Gallagher C, Hawryluk GWJ, Iaccarino C, Joseph M, Khan T, Laeke T, Levchenko O, Liu B, Liu W, Maas A, Manley GT, Manson P, Mazzeo AT, Menon DK, Michael DB, Muehlschlegel S, Okonkwo DO, Park KB, Rosenfeld JV, Rosseau G, Rubiano AM, Shabani HK, Stocchetti N, Timmons SD, Timofeev I, Uff C, Ullman JS, Valadka A, Waran V, Wells A, Wilson MH, Servadei F (2019) Consensus statement from the International Consensus Meeting on the Role of Decompressive Craniectomy in the Management of Traumatic Brain Injury : Consensus statement. *Acta Neurochir (Wien)* 161 (7):1261-1274. doi:10.1007/s00701-019-03936-y

Declarations

Ethics approval: An ethics waiver was obtained from the CHU de Québec – Université Laval research ethics board.

Consent for publication: Not applicable

Availability of data and materials: The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Competing interests: The authors declare they have no competing interests.

Funding: This research was supported by the *Canadian Institutes of Health Research* (Foundation grant, #353374 and Embedded Clinician Researcher (PA)). Drs Moore, Lauzier, Archambault, Lamontagne and Chassé are recipients of a research salary Award from the *Fonds de Recherche du Québec – Santé* (FRQS). Dr Turgeon is the Canada Research Chair in Critical Care Neurology and Trauma. The funders had no role in developing this protocol.

Authors contributions:

LM contributed substantially to the conception and design of the study, the acquisition of data, the analysis, the interpretation of the data, and drafted the article

PAT contributed substantially to the conception and design of the study, the acquisition of data, the analysis, the interpretation of the data, critical revision of the article and provided final approval of the version submitted for publication

FL contributed substantially to the conception and design of the study, the interpretation of the data, the analysis, critical revision of the article and provided final approval of the version submitted for publication

PA contributed substantially to the conception and design of the study, the interpretation of the data, critical revision of the article and provided final approval of the version submitted for publication

FL contributed substantially to the conception and design of the study, the interpretation of the data, critical revision of the article and provided final approval of the version submitted for publication

MC contributed substantially to the conception and design of the study, the interpretation of the data, critical revision of the article and provided final approval of the version submitted for publication

HTS contributed substantially to the conception and design of the study, the interpretation of the data, critical revision of the article and provided final approval of the version submitted for publication

BG contributed substantially to the conception and design of the study, the interpretation of the data, critical revision of the article and provided final approval of the version submitted for publication

FL contributed substantially to the conception and design of the study, the interpretation of the data, critical revision of the article and provided final approval of the version submitted for publication

JK contributed substantially to the conception and design of the study, the interpretation of the data, critical revision of the article and provided final approval of the version submitted for publication

PLB contributed substantially to the conception and design of the study, the interpretation of the data, critical revision of the article and provided final approval of the version submitted for publication

CT contributed substantially to the conception and design of the study, the interpretation of the data, critical revision of the article and provided final approval of the version submitted for publication

FL contributed substantially to the conception and design of the study, the interpretation of the data, the analysis, critical revision of the article and provided final approval of the version submitted for publication

Acknowledgements: Not applicable

Tables

Table 2. Synthesis of results for diagnostic interventions

First author and year of publication of review	Studies (n) (RCT; prospective; retrospective; other)	Patients (n)	AMSTAR-2 ^a	Patients with primary outcome (%) ^b	Heterogeneity χ^2 , Q or I ²	Studies at low risk of bias, n ^c
Head CT in adults with acute mild TBI at low-risk on a validated clinical decision rule						
Intracranial injury						
Pandor et al. 2011 <i>CCHR (high risk criteria)</i> <i>CHIP</i> <i>New Orleans Criteria</i> <i>NEXUS-II</i>	0; 5; 1; 0 0; 1; 0; 0 0; 5; 1; 0 0; 2; 0; 0	17,152 3,181 13,334 21,683	Moderate	0 to 4.52% ^g 1.21% ^g 0 to 2.89% ^g 0.46 to 0.90% ^g	NA	0/6 ^d 0/1 ^d 0/6 ^d 0/2 ^d
Routine repeat head CT in absence of neurological deterioration in adults with acute mild complicated TBI^e						
Progression of intracranial traumatic hemorrhage on repeat CT						
Stippler et al. 2012	0; 8; 7; 4	1,630	Critically low	19.9% ^h	NR	0/19
Almenawer et al. 2013	0; 8; 4; 0	2,120	Critically low	22.4% ^g	NR	NR
Marincowitz et al. 2018	0; 2; 12; 0	NR	Critically low	20.4% (14.7-26.7)	I ² =97.9%	NR
Routine repeat head CT in absence of neurological deterioration in adults with acute mild TBI on anticoagulant or antiplatelet therapy^f						
Delayed intracranial hemorrhage						
Chauny et al. 2016	0; 3; 4; 0	1,594	Critically low	0.6% (0.0-1.2)	NR	0/7

AMSTAR, Assessing the Methodological Quality of Systematic Reviews; CCHR, Canadian CT Head Rule; CHIP, CT in Head Injury Patients; CI, confidence intervals; CT, computed tomography; NA, not applicable; NEXUS-II, the National Emergency X-Radiography Utilisation Study II; NR, not reported; P, proportion; RCT, randomized controlled trials; TBI, traumatic brain injury

^aInterpretation of AMSTAR-2: High: no or one non-critical weakness, Moderate: more than one non-critical weakness, Low: one critical flaw with or without non-critical weaknesses, Critically low: more than one critical flaw with or without non-critical weaknesses

^bFalse omission rate, calculated as $\llcorner 1 - \text{negative predictive value (i.e., true negatives / [true negatives + false negatives])} \gg$

^cAs reported in systematic review

^dNumber of studies $\geq 70\%$ items

^eMild TBI with abnormal initial head CT

^fMild TBI with normal initial head CT

^gRange of values from included studies

^hPooled estimate from included studies (CI not reported)

Table 3. Synthesis of results for therapeutic interventions

First author and year of publication of review	Studies, n (RCT; prosp.; retrosp.; other)	Patients(n)	AMSTAR-2 ^a	OR or RR on primary outcome (95% CI)	Heterogeneity χ^2 , Q or I ²	Low risk of bias (n) ^b	GRADE; Credibility of evidence ^c
Platelet transfusion in adults with acute traumatic brain injury on antiplatelet therapy							
Mortality							
Kumar et al. 2015 <i>With thrombocytopenia</i> <i>Without thrombocytopenia</i>	0; 0; 5; 0 0; 0; 1; 0	804 108	Moderate	OR: 1.55 (0.75-3.18) OR: 7.59 (0.36-162)	I ² =68% NA	0/5 0/1	Very low; NS Very low; NS
Leong et al. 2015	0; 0; 4; 0	711	Critically low	OR: 1.77 (1.00-3.13)	I ² =36%	2/4 ^d	NR; NS
Antibiotic prophylaxis in adults with basal skull fractures							
Meningitis							
Ratilal et al. 2015 <i>With CSF leakage</i> <i>Without CSF leakage</i>	3; 0; 0; 0 2; 0; 0; 0	92 106	Moderate	OR: 0.44 (0.09-2.15) OR: 0.77 (0.25-2.41)	I ² =0% NR	2/3 ^d 1/2 ^d	Moderate; NS Moderate; NS
Antibiotic prophylaxis for external ventricular drain placement in adults with acute traumatic brain injury							
Infections							
Ratilal et al. 2010	1; 0; 0; 0	52	High	OR: 1.08 (0.06-18.3)	NA	NR	NR; NS
Extended seizure prophylaxis >1 week in adults with severe TBI							
Late seizures^e							
Temkin et al. 2001 <i>Carbamazepine</i> <i>Phenobarbital</i> <i>Phenobarbital+Phenytoin</i> <i>Phenytoin</i> <i>Valproate</i>	1; 0; 0; 0 1; 0; 0; 0 1; 0; 0; 0 4; 0; 0; 0 1; 0; 0; 0	110 163 148 812 344	Critically low	RR: 0.70 RR: 0.33 RR: 1.50 RR: 0.45 RR: 1.73 RR: 0.36 (0.08-1.73) RR: 1.08 (0.76-1.55) RR: 1.28 (0.76-2.16)	NR NR NR NR NR	NR	NR; NS NR; NS NR; NS NR; NS NR; NS
Chang et al. 2003 <i>Carbamazepine+phenytoin+valproate</i>	5; 0; 0; 0	1,312	Critically low	RR: 1.05 (0.82-1.35)	NR	2/5	NR; NS
Thompson et al. 2015 <i>Carbamazepine+phenytoin</i>	6; 0; 0; 0	1,029	Moderate	RR: 0.91 (0.57-1.47)	I ² =54%	2/6 ^d	Very low; NS
Wilson et al. 2018 <i>Levetiracetam</i> <i>Phenytoin</i>	2; 0; 0; 0 3; 0; 1; 0	164 716	Critically low	OR: 0.69 (0.24-1.96) OR: 0.40 (0.10-1.60)	NR NR	2/2 4/4	High; NS High; NS
Therapeutic hypothermia in adults with acute severe traumatic brain injury							
GOS or GOS-E - unfavorable outcome							

Harris et al. 2002	4; 0; 0; 0	499	Critically low	OR: 0.61 (0.5-1.14)	$\chi^2=6.9$	0/4	NR; NS
Henderson et al. 2003	8; 0; 0; 0	748	Critically low	OR: 0.75 (0.6-1.10)	$\chi^2=16.6$	3/8	NR; NS
McIntyre et al. 2003	10; 0; 0; 0	779	Low	RR: 0.78 (0.6-0.98)	Q=16.1	2/10	NR; IV
Bratton et al. 2007	6; 0; 0; 0	694	Critically low	RR: 0.68 (0.5-0.89)	$I^2=48\%$	0/6 ^f	NR; IV
Peterson et al. 2008	12; 0; 0; 0	1,294	Low	RR: 0.73 (0.59-0.90)	$I^2=59\%$	1/12	NR; IV
Sydenham et al. 2009 <i>All studies</i> <i>Low risk of bias</i>	20; 0; 0; 0 0 8; 0; 0; 0	1,382 686	Low	OR: 0.69 (0.55-0.86) OR: 0.79 (0.57-1.08)	$I^2=38\%$ $I^2=0\%$	8/20 8/8	NR; IV NR; NS
Fox et al. 2010	10; 0; 0; 0	1,223	Moderate	RR: 0.66 (0.56-0.78)	$I^2=34\%$	7/10	II
Georgiou et al. 2013 <i>All studies</i> <i>Low risk of bias</i>	18; 0; 0; 0 0 3; 0; 0; 0	1,733 670	Low	RR: 0.81 (0.73-0.89) RR: 1.07 (0.92-1.24)	$I^2=63\%$ $I^2=1\%$	3/18 3/3	Low; III Low; NS
Crossley et al. 2014 <i>All studies</i> <i>Low risk of bias</i>	20; 0; 0; 0 0 16; 0; 0; 0 0	1,885 964	High	RR: 0.67 (0.78-0.57) RR: 0.60 (0.52-0.69)	$I^2=51\%$ $I^2=0\%$	16/20 16/16	NR; II NR; IV
Li et al. 2014	10; 1; 0; 0 0	1,029	Critically low	RR: 0.83 (0.65-1.05)	$I^2=61\%$	NR	NR; NS
Zhu et al. 2016 <i>All studies</i> <i>Low risk of bias</i>	11; 0; 0; 0 0 5; 0; 0; 0	1,651 781	Moderate	RR: 0.80 (0.63-1.00) RR: 0.84 (0.62-1.15)	$I^2=78\%$ $I^2=76\%$	5/11 5/5	NR; NS NR; NS
Crompton et al. 2017	20; 14; 1; 0	3,109	Critically low	RR: 0.74 (0.65-0.85)	$I^2=53\%$	NR	NR; III
Leng et al. 2017	7; 0; 0; 0	1,324	Critically low	OR: 1.00 (0.79-1.21)	$I^2=68\%$	NR	NR; NS
Zang et al. 2017	21; 0; 0; 0 0	2,302	Critically low	RR: 0.71 (0.60-0.84)	$I^2=72\%$	10/21	NR; III
Watson et al. 2018 <i>All studies</i> <i>Low risk of bias</i>	22; 0; 0; 0 0 2; 0; 0; 0	2,346 522	Low	RR: 0.81 (0.75-0.87) RR: 1.16 (1.02-	$I^2=71\%$ $I^2=0\%$	2/22 2/2	NR; II NR; IV

					1.32)			
Decompressive craniectomy in adults with severe traumatic brain injury								
GOS/GOS-E - unfavorable outcome								
Wang et al. 2016	2; 0; 0; 0	175	Critically low		1/2	NR; NS		
Zhang et al. 2017	4; 0; 0; 0	645	Critically low		2/4	NR; NS		
Tsaousi et al. 2018	3; 0; 0; 0	564	Low		2/3	NR; NS		
Lu et al. 2019	4; 0; 0; 0	622	Critically low		0/4	NR; NS		

AMSTAR, Assessing the Methodological Quality of Systematic Reviews; CI, confidence intervals; CSF, cerebrospinal fluid; CT, computed tomography; GOS-E, Glasgow Outcome Scale-Extended; GRADE, Grading of Recommendations Assessment, Development and Evaluation; NA, not applicable; NEXUS-II, the National Emergency X-Radiography Utilisation Study II; NR, not reported; OR, odds ratio; P, proportion; RR, relative risks; RCT, randomized controlled trials; TBI, traumatic brain injury; ^aAMSTAR-2 interpretations: High: no or one non-critical weakness, Moderate: more than one non-critical weakness, Low: one critical flaw with or without non-critical weaknesses, Critically low: more than one critical flaw with or without non-critical weaknesses; ^bAs reported in systematic review ^cII (Highly suggestive evidence): $n > 1000$, $P < 0.000001$ for pooled estimate, largest study $p < 0.05$; III (suggestive evidence): $n > 1000$ and $p < 0.001$ for pooled estimate; IV (weak evidence): $p < 0.05$ for pooled estimate; NS (nonsignificant association): $p > 0.05$ for pooled estimate; ^dNumber of studies $\geq 70\%$ items; ^eAntiepileptic drugs were compared to either placebo, no treatment or other pharmacologic agents; ^fSeven RCTs at high risk of bias were excluded

Figures




Figure 1

Preferred Reporting Items for Systematic Reviews and Meta-analysis flow diagram

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [SDC5.AMSTAR2v2.docx](#)
- [SDC4.Referencesofstudiesexcluded.docx](#)
- [SDC1.PICOSforeachclinicalpractice.docx](#)
- [SDC2.ResearchstrategiesinPubMed.docx](#)
- [SDC6.SynthesisofresultsforsecondaryoutcomesV2.docx](#)
- [SDC3.CharacteristicsofincludedSRv2.docx](#)